Subscribe to Updates
Get the latest creative news from FooBar about art, design and business.
Browsing: Alzheimer’s
Breakthrough Trial Suggests GLP-1 Drugs Could Slow Alzheimer’s Progression Researchers have discovered that GLP-1 drugs, like liraglutide, may slow cognitive…
Recent advances reveal that an epilepsy drug may reverse Alzheimer’s symptoms, paving the way for innovative dementia treatments.
This article explores the therapeutic potential of Schisandrin B (Sch B), a compound found in the Traditional Chinese Medicine (TCM)…
Discover comprehensive Memory Care Centers (MCCs) at Metro Manila’s top hospitals – Makati Medical Center, Cardinal Santos Medical Center, and De Los Santos Medical Center. These specialized facilities offer personalized services for Alzheimer’s and dementia patients, including neurological testing, innovative treatments, and supportive care management. Learn about the prevalence of dementia in the Philippines and the essential services provided by these MCCs to enhance the quality of life for affected individuals. Join the movement towards improved mental wellness and healthcare accessibility in the country.
World Alzheimer’s Day, celebrated globally every 21st September, serves as a watershed moment for raising awareness and combating the stigma of Alzheimer’s disease. Particularly in Asia, where a staggering 23 million individuals are estimated to be living with dementia, this day has played a crucial role in sparking conversations and urging interventions.
The FDA is poised to make a decision on granting approval to Leqembi – the first drug to show promise in slowing Alzheimer’s disease.
A novel Alzheimer’s disease treatment drug, lecanemab, developed by Japanese pharmaceutical company Eisai and US firm Biogen, is nearing full approval in the US. Excitement is also building in Japan where the population of Alzheimer’s patients is growing and Prime Minister Fumio Kishida has prioritised dementia. The drug is undergoing an expedited review by the Japanese Pharmaceuticals and Medical Devices Agency and could potentially be approved this autumn.
Eli Lilly’s Alzheimer’s medication donanemab shows significant potential in slowing cognitive decline. Find out more
In Asia Pacific, the number of people suffering from dementia is set to triple from 23 million in 2015 to 71 million by 2050.
Lecanemab is one of the first experimental drugs for dementia which appears to help in slowing down the progression of cognitive decline.
Subscribe to Updates
Subscribe to receive latest health related news from us
The contents on Medical Channel Asia are for general educational purposes only.
It is not intended to be a substitute for professional medical advice, treatment, or diagnosis.
See additional information.